OptiBiotix (OPTI) has this morning published FY17 interims (Nov16-May17) that highlight the continuing commercial development being made by management for both SweetBiotix and LP-LDL. Reported income was broadly flat at £0.1m (1H16 +£0.1m) with adj. loss of £0.9m (+£3.1m profit when including a £4.1m non-cash profit on revaluation of its investment in Skin Biotherapeutics – SBTX revaluation). Adj. LPS was 1.3p compared with 0.8p (1H16 LfL) and is due to inc
30 Aug 2017
OPTI (Outlook Positive Trending Interims)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
OPTI (Outlook Positive Trending Interims)
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
30 Aug 2017 -
Author:
Mark Brewer | Cavendish Research -
Pages:
12
OptiBiotix (OPTI) has this morning published FY17 interims (Nov16-May17) that highlight the continuing commercial development being made by management for both SweetBiotix and LP-LDL. Reported income was broadly flat at £0.1m (1H16 +£0.1m) with adj. loss of £0.9m (+£3.1m profit when including a £4.1m non-cash profit on revaluation of its investment in Skin Biotherapeutics – SBTX revaluation). Adj. LPS was 1.3p compared with 0.8p (1H16 LfL) and is due to inc